These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38741224)

  • 21. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review.
    Moe J; Godwin J; Purssell R; O'Sullivan F; Hau JP; Purssell E; Curran J; Doyle-Waters MM; Brasher PMA; Buxton JA; Hohl CM
    CJEM; 2020 Mar; 22(2):178-186. PubMed ID: 31955714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The need for multiple naloxone administrations for opioid overdose reversals: A review of the literature.
    Abdelal R; Banerjee AR; Carlberg-Racich S; Darwaza N; Ito D; Epstein J
    Subst Abus; 2022; 43(1):774-784. PubMed ID: 35112993
    [No Abstract]   [Full Text] [Related]  

  • 23. Naloxone interventions in opioid overdoses: a systematic review protocol.
    Shaw LV; Moe J; Purssell R; Buxton JA; Godwin J; Doyle-Waters MM; Brasher PMA; Hau JP; Curran J; Hohl CM
    Syst Rev; 2019 Jun; 8(1):138. PubMed ID: 31186071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply.
    Bell A; Bennett AS; Jones TS; Doe-Simkins M; Williams LD
    Subst Abus; 2019; 40(1):52-55. PubMed ID: 29558283
    [No Abstract]   [Full Text] [Related]  

  • 25. Fentanyl causes naloxone-resistant vocal cord closure: A platform for testing opioid overdose treatments.
    Miner NB; Schutzer WE; Zarnegarnia Y; Janowsky A; Torralva R
    Drug Alcohol Depend; 2021 Oct; 227():108974. PubMed ID: 34492557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit.
    Pergolizzi JV; Dahan A; Ann LeQuang J; Raffa RB
    J Clin Pharm Ther; 2021 Dec; 46(6):1501-1504. PubMed ID: 34111307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids.
    Dahan A; Franko TS; Carroll JW; Craig DS; Crow C; Galinkin JL; Garrity JC; Peterson J; Rausch DB
    Front Public Health; 2024; 12():1346109. PubMed ID: 38481848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
    McDonald R; Danielsson Glende Ø; Dale O; Strang J
    Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid education and nasal naloxone rescue kits in the emergency department.
    Dwyer K; Walley AY; Langlois BK; Mitchell PM; Nelson KP; Cromwell J; Bernstein E
    West J Emerg Med; 2015 May; 16(3):381-4. PubMed ID: 25987910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose.
    Krotulski AJ; Chapman BP; Marks SJ; Ontiveros ST; Devin-Holcombe K; Fogarty MF; Trieu H; Logan BK; Merchant RC; Babu KM
    Clin Toxicol (Phila); 2022 Feb; 60(2):197-204. PubMed ID: 34278904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.
    Fairbairn N; Coffin PO; Walley AY
    Int J Drug Policy; 2017 Aug; 46():172-179. PubMed ID: 28687187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest.
    Mann J; Samieegohar M; Chaturbedi A; Zirkle J; Han X; Ahmadi SF; Eshleman A; Janowsky A; Wolfrum K; Swanson T; Bloom S; Dahan A; Olofsen E; Florian J; Strauss DG; Li Z
    Clin Pharmacol Ther; 2022 Nov; 112(5):1020-1032. PubMed ID: 35766413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring a Crisis: Questioning the Use of Naloxone Administrations as a Marker for Opioid Overdoses in a Large U.S. EMS System.
    Grover JM; Alabdrabalnabi T; Patel MD; Bachman MW; Platts-Mills TF; Cabanas JG; Williams JG
    Prehosp Emerg Care; 2018; 22(3):281-289. PubMed ID: 29297739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bystander preference for naloxone products: a field experiment.
    Marks KR; Oyler DR; Strickland JC; Jaggers J; Roberts MF; Miracle DK; Barnes C; Lei F; Smith A; Mackin E; Martin MC; Freeman PR
    Harm Reduct J; 2023 Nov; 20(1):171. PubMed ID: 38017424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.
    Dunn KE; Barrett FS; Bigelow GE
    Addict Behav; 2018 Nov; 86():56-60. PubMed ID: 29625751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users.
    Acharya M; Chopra D; Hayes CJ; Teeter B; Martin BC
    Value Health; 2020 Apr; 23(4):451-460. PubMed ID: 32327162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods.
    Ashrafioun L; Gamble S; Herrmann M; Baciewicz G
    Subst Abus; 2016; 37(1):76-81. PubMed ID: 26514071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event.
    Alexander M; Hooker J; Stratton M; Huh M; Houck K
    J Am Pharm Assoc (2003); 2024; 64(3):101999. PubMed ID: 38151200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.